Non‐glycaemic effects mediated via GLP‐1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
The glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) liraglutide and exenatide can improve glycaemic control by stimulating insulin release through pancreatic β ‐cells in a glucose‐dependent manner. GLP‐1 receptors are not restricted to the pancreas; therefore, GLP‐1 RAs cause additional non‐glycaemic effects. Preclinical and clinical trial data suggest a multitude of additional beneficial effects related to GLP‐1 RA therapy, including improvements in β ‐cell function, systolic blood pressure and body weight. These effects are of a particular advantage to patients with type 2 diabetes, as most are affected by β ‐cell dysfunction, obesity and hypertension. Transient gastrointestinal adverse events, such as nausea and diarrhoea, are also common. To improve gastrointestinal tolerability, an incremental dosing approach is used with liraglutide and exenatide twice daily. A potential protective role for GLP‐1 RAs in the cardiovascular and central nervous systems has been suggested from animal studies and short‐term clinical trials. These effects and other safety aspects of GLP‐1 therapy are currently being investigated in ongoing long‐term clinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Steen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · cited 1×
“Insulin receptor desensitisation, similar to that seen in T2D, has been observed in the brain of Alzheimer’s patients, resulting in the coining of the term ‘type 3 diabetes’ [95].”
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“In support of these extra-pancreatic effects, clinical trials with GLP-1 RAs have shown potential improvements in body weight [20], systolic blood pressure (SBP) and β-cell function [9,10,12,14,16,17].”
BackgroundBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 1×
“In support of these extra-pancreatic effects, clinical trials with GLP-1 RAs have shown potential improvements in body weight [20], systolic blood pressure (SBP) and β-cell function [9,10,12,14,16,17].”
BackgroundGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“Liraglutide-induced weight loss in human beings may be attributed to feelings of satiety and fullness [87] that results in a decreased energy intake [88].”
BackgroundBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 2×
“After 6 weeks’ infusion with either GLP-1 or saline, patients with T2D who were receiving GLP-1 had a greater percentage weight loss at study end than patients receiving saline [32] (figure 3).”
BackgroundKendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 2×
“Pharmacological levels of GLP-1, achieved through continuous GLP-1 infusion, have been shown to normalise fasting blood glucose levels [3]; however, the therapeutic potential of native GLP-1 is limited because of its short (1–2 min) half-life following rapid degradation by dipeptidyl peptidase-4 (DPP-4) [4].”
BackgroundInfluentialDrucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Self-citationVilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · cited 2×
“In phase 3 clinical trials, improvements in glycaemic control occurred in patients with type 2 diabetes treated with agents from both of these classes of incretin-based therapies [6–18]; however, efficacy is more pronounced with GLP-1 RAs, which provide the additional benefit of promoting weight loss [19].”
BackgroundRisk Factors for Renal Dysfunction in Type 2 Diabetes
Retnakaran, R., Cull, C. A., Thorne, K. I., Adler, A. I., Holman, R. R., & for the UKPDS Study Group (2006) · Diabetes · doi:10.2337/db05-1620 · Cited by 927
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 1×
“Patients with acute myocardial infarction and angioplasty who received a 72-h infusion of GLP-1 experienced improved cardiac function that reduced in-hospital mortality rate and the duration of hospitalisation [41].”
BackgroundZinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848 · cited 1×
“In support of these extra-pancreatic effects, clinical trials with GLP-1 RAs have shown potential improvements in body weight [20], systolic blood pressure (SBP) and β-cell function [9,10,12,14,16,17].”
Backgroundon behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699
Nyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680
Sokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 656
Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575
Goldstein, B. J., Feinglos, M. N., Lunceford, J. K., Johnson, J., Williams-Herman, D. E., & for the Sitagliptin 036 Study Group (2007) · Diabetes Care · doi:10.2337/dc07-0627 · Cited by 509
Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats
Farilla, L., Hui, H., Bertolotto, C., Kang, E., Bulotta, A., Di Mario, U., & Perfetti, R. (2002) · Endocrinology · doi:10.1210/en.2002-220405 · Cited by 502 · cited 2×
“Zucker diabetic fatty rats (ZDF) exhibited improved glycaemic control following a 2-day continuous infusion of GLP-1 [27].”
BackgroundWei, Y., & Mojsov, S. (1995) · FEBS Letters · doi:10.1016/0014-5793(94)01430-9 · Cited by 450
Blevins, T., Pullman, J., Malloy, J., Yan, P., Taylor, K., Schulteis, C., Trautmann, M., & Porter, L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2081 · Cited by 448
Vilsbøll, T., Agersø, H., Krarup, T., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021053 · Cited by 444 · cited 4×
“E-mail: agarber@bcm.tmc.edu Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms vildagliptin, alogliptin, saxagliptin and linagliptin), and DPP-4-resistant GLP-1 receptor agonists (GLP-1 RAs; liraglutide once daily, exenat…”
BackgroundInfluentialSelf-citationGlucagon-Like Peptide 1 Induces Natriuresis in Healthy Subjects and in Insulin-Resistant Obese Men
Gutzwiller, J.-P., Tschopp, S., Bock, A., Zehnder, C. E., Huber, A. R., Kreyenbuehl, M., Gutmann, H., Drewe, J., Henzen, C., Goeke, B., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031403 · Cited by 442
Young, A. A., Gedulin, B. R., Bhavsar, S., Bodkin, N., Jodka, C., Hansen, B., & Denaro, M. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1026 · Cited by 440
Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60406-0 · Cited by 434
DeFronzo, R. A., Hissa, M. N., Garber, A. J., Luiz Gross, J., Yuyan Duan, R., Ravichandran, S., Chen, R. S., & for the Saxagliptin 014 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1984 · Cited by 416
Self-citationBlonde, L., Klein, E. J., Han, J., Zhang, B., Mac, S. M., Poon, T. H., Taylor, K. L., Trautmann, M. E., Kim, D. D., & Kendall, D. M. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00602.x · Cited by 416
Bunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1797 · Cited by 388
Protection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4
Perry, T., Haughey, N. J., Mattson, M. P., Egan, J. M., & Greig, N. H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.037481 · Cited by 380 · cited 1×
“Additionally, GLP-1 and exendin-4 administration provides complete protection from glutamateinduced apoptosis in cultured rat hippocampal cells [73].”
BackgroundPerry, T., Lahiri, D. K., Sambamurti, K., Chen, D., Mattson, M. P., Egan, J. M., & Greig, N. H. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10611 · Cited by 347
Jendle, J., Nauck, M. A., Matthews, D. R., Frid, A., Hermansen, K., Düring, M., Zdravkovic, M., Strauss, B. J., Garber, A. J., & Groups, O. B. O. T. L. A. L. S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01158.x · Cited by 312
Self-citationBunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Taskinen, M.-R., Smith, U., Yki-Järvinen, H., & Diamant, M. (2011) · Diabetes Care · doi:10.2337/dc11-0291 · Cited by 240 · cited 1×
“028), suggesting a possible sustained improvement in β-cell health [35].”
BackgroundMcClean, P. L., Gault, V. A., Harriott, P., & Hölscher, C. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.12.023 · Cited by 193
Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism
Nyström, T., Gonon, A. T., Sjöholm, Å., & Pernow, J. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.08.024 · Cited by 188 · cited 1×
“Expression of GLP-1 RAs has been shown in coronary arterial endothelial cells [39]; however, in vitro studies revealing a dose-dependent vasorelaxant effect of GLP-1 on rat femoral artery rings mediated by GLP-1 receptor binding also showed that the effect remained intact after the mechanical removal of the endotheliu…”
ResultGlucagon-Like Peptide-1 Is Involved in Sodium and Water Homeostasis in Humans
Gutzwiller, J.-P., Hruz, P., Huber, A. R., Hamel, C., Zehnder, C., Drewe, J., Gutmann, H., Stanga, Z., Vogel, D., & Beglinger, C. (2006) · Digestion · doi:10.1159/000094334 · Cited by 127 · cited 2×
“In healthy human beings, GLP-1 infusion decreased renal sodium reabsorption following either an intravenous or an oral salt load [61].”
BackgroundGLP-1 amplifies insulin signaling by up-regulation of IRβ, IRS-1 and Glut4 in 3T3-L1 adipocytes
Gao, H., Wang, X., Zhang, Z., Yang, Y., Yang, J., Li, X., & Ning, G. (2007) · Endocrine · doi:10.1007/s12020-007-9011-4 · Cited by 77 · cited 1×
“However, GLP-1 receptor activation has been reported to reverse neuronal insulin receptor desensitisation [96], and as exendin(9-39) [97] and liraglutide [98] are both capable of crossing the blood-brain barrier, GLP-1 RAs may provide protection against neurodegeneration via this mechanism.”
Background
Cited by
Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
van Bloemendaal, L., ten Kulve, J. S., la Fleur, S. E., Ijzerman, R. G., & Diamant, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0414 · Cited by 312
“Many excellent reviews have been published describing the physiological role of GLP-1 in glucose regulation and the pleiotropic effects (Baggio & Drucker 2004, Drucker 2006, Holst 2007, van Genugten et al. 2009, Vilsboll & Garber 2012).”
GLP ‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond
Ryan, D., & Acosta, A. (2015) · Obesity · doi:10.1002/oby.21107 · Cited by 112
“Accumulating evidence from preclinical and clinical studies indicates that the effects of GLP-1 receptor agonists go beyond glycemic control and weight reduction alone (15,16).”
BackgroundTime course and mechanisms of the anti‐hypertensive and renal effects of liraglutide treatment
von Scholten, B. J., Lajer, M., Goetze, J. P., Persson, F., & Rossing, P. (2015) · Diabetic Medicine · doi:10.1111/dme.12594 · Cited by 73
Kaur, M., & Misra, S. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03646-0 · Cited by 51
Sbraccia, P., Aberle, J., Olsen, A. H., Rathor, N., & Major‐Pedersen, A. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14945 · Cited by 3
“loss.(2,3,6-12) A higher dose of liraglutide was therefore tested specifically for use in weight management, with further phase III trials revealing significant weight loss in individuals with obesity, or overweight with or without T2D.”
Background
Metadata
- Authors
- Vilsbøll, T., & Garber, A. J.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2012-03-08
- Volume
- 14
- Issue
- s2
- Pages
- 41-49
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1970656852
- Cited by
- 30
- References
- 40
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.